馬兜鈴酸、Statin類藥物與阿斯匹靈在末期腎病患者泌尿上皮癌的角色

Role of Aristolochic Acid, Statins, and Aspirin on the Risk of Urothelial Cancer in Patients With End-Stage Renal Disease

王碩盟(Shuo-Meng Wang)

指導教授 ： 陳保中

共同指導教授 ： 王榮德(Jung-Der wang)

國立臺灣大學/公共衛生學院/職業醫學與工業衛生研究所/博士(2014年)

https://doi.org/10.6342/NTU.2014.01810

摘要

前言: 在台灣，末期腎病變及上泌尿道上皮癌發生率在已知報告都相當高，女性比例也較高。我們已經使用國衛院健保資料庫分出洗腎及泌尿道癌症的發生率及盛行率，並推演可能相關疾病及藥物的使用的影響。由於超過99%病人皆不住在已知的南台灣含砷地區，而可能發生原因如止痛藥、含馬兜鈴酸中草藥都值得探討，另外對於一些抗發炎藥物可能具有預防癌症發生的效果，對末期腎病變病人的泌尿道上皮癌的角色也值得探討。另外，在2003年11月衛生署禁止使用五種含馬兜鈴酸藥材，對於泌尿道上皮癌的影響也值得探討。
研究方法與對象:我們使用健保資料庫重大傷病檔1997-2002, 1997-2008及100萬人抽樣檔資料進行研究，進行四種研究設計。首先使用1997-2002年資料，並以台灣人口為對照組計算泌尿道上皮癌族群的泌尿系統癌症的年紀、性別分層標準發生率，接著使用個人的藥物累積來計算末期腎病變病人透析後新發生泌尿上皮癌發生風險。接著使用1997-2008 資料進行第三、四部分，計算40-84歲末期腎病變病人的逐年標準發生率及累積發生率，計算變化的趨勢，最後加入可能造成及預防泌尿上皮癌的因子，作多變數分析。
結果: 使用1997-2002健保資料庫，在58739位末期腎病變病人中找出687位透析後新發生泌尿上皮癌，以台灣人口為對照組，標準發生率在泌尿道癌症是12.9(95% CI:12.0-13.9)。而女性的22.1 (20.1, 24.3)及小於50歲的74.5 (1.8, 41.2)更是不成比例高。另外在分析由320位透析後新發生泌尿上皮癌病人的資料(由38995位末期腎病變病人) ，使用木通或累計馬兜鈴酸1-100mg或更高都會明顯增加泌尿上皮癌，而超過150顆止痛藥也明顯增加風險。
由1997-2008健保資料庫，分析2708位透析後新發生泌尿上皮癌病人的資料(由90477位洗腎病人，40-84歲族群)，女性的上泌尿道泌尿上皮癌標準發生率及累積發生率在2000年後都有減少趨勢，可能與1998年後中草藥使用含馬兜鈴酸的藥才減少有關。
由1997-2008健保資料庫，分析1243位末期腎病變後新發生泌尿上皮癌病人的資料(由98243位洗腎病人)，使用乙醯胺酚或累計馬兜鈴酸在1-100mg或更高都會明顯增加泌尿上皮癌，使用木通也明顯增加膀胱癌風險，但是在超過60g才增加上泌尿道泌尿上皮癌風險。而使用statin類藥物及阿斯匹靈可明顯發現減少泌尿上皮癌風險，但是如果累計馬兜鈴酸劑量超過100mg則無效。
結論: 暴露含馬兜鈴酸中草藥與末期腎病變病患產生泌尿上皮癌有關，在逐年減少使用後，女性洗腎患者的上泌尿道泌尿上皮癌也呈現減少趨勢，除馬兜鈴酸外，乙醯胺酚也是一個可能的相關致病因子，另一方面，使用statin類藥物及阿斯匹靈可明顯發現減少泌尿上皮癌風險，但是如果累計馬兜鈴酸劑量超過100mg則無效。所以，雖然已經減少使用含馬兜鈴酸成分的中草藥，但是末期腎病變病人的泌尿上皮癌風險至2008底仍處於高點。在我們這一代，馬兜鈴酸對於公共衛生的影響無庸置疑。雖然對於致病因子及保護因子的進一步了解令人鼓舞，但是實際對國人健康的增進仍有距離，制定有效的管制方法有其急迫性。

關鍵字

泌尿上皮癌 ； 末期腎病變 ； 馬兜鈴酸 ； 乙醯胺酚 ； 阿斯匹靈 ； HMG-CoA 還原酶抑制劑 ； 標準發生率 ； 累積發生率

並列摘要

Background and Purpose: Both end-stage renal disease (ESRD) and upper tract urothelial cancer (UTUC) bear high incidence rates in Taiwan. Female is also observed higher in development of urinary tract cancer (UTC). We can use National Health Research Institute database (NHRID) to calculate incidence and prevalence rate, and to deduce possible caution and prevention factor, including relation disease and consumption of medicine. Arsenic is a potential confounder although more than 99% of UC cases resided in area out of 4 traditional endemic areas of arsenic in Southwest Taiwan. Other possible predisposing factors include analgesics, aristolochic acid (AA) containing Chinese herbal products (CHP). Some anti-inflammation agents are also potential chemoprevention for occurrence of UC in chronic dialysis patient. Otherwise, in Nov 2003 prohibition of 5 herbal components containing AA was promulgated by the Department of Health. This policy may have impact on development of UC.
Methods: We used NHIRD 1997-2002, 1997-2008 and 1,000,000 randomized samples as our study database. There are four designs to answer different questions. First, we used 1997-2002 NHIRD data to calculate standardized incidence ratios (SIRs) of urinary tract cancer among ESRD and general population as reference. Second, cox-regression model to calculate hazard ratios of UC in ESRD with factors of AA-CHP, analgesics and acetaminophen from NHIRD claims. Third, using 1997-2008 NHIRD, we calculated 40-84 y/o cumulative incidence rate (CIR40-84) and SIR40-84 and tested trend by calendar year. Fourth, using 1997-2008 NHIRD we put potential caution and prevention agents on UC among ESRD.
Results: Using 1997-2002 NHIRD, there are 687 new developed UTC among 58,739 patients with ESRD. Using the general population as the reference group, SIRs were 12.9 (95% CI (confidence interval): 12.0-13.9) for all UTC cases. SIRs are disproportionate high in female of 22.1 (95% CI: 20.1, 24.3) and younger, namely, less than 50 y/o of 74.5 (95% CI: 1.8, 41.2). Another similar period study sorting 320 patients developed UC after ESRD from 38,995 ESRD patients. Having been prescribed Mu Tong or an estimated consumption of aristolochic acid (esAA) more than 1-100 mg, were both associated with an increased risk of UC in the multivariable analyses. Analgesic consumption of more than 150 pills was also associated with an increased risk of UC.
Another study sorting 2,708 new developed UC from 90,477 ESRD between1997 and 2008 covering the patients aged 40-85. The time trends of CIR40-84 and SIR40-84 of UTUC in females appear to decline after calendar year 2000. These trends may be related to AA-associated herbal products after 1998.
Moreover, during 1998-2008 data, 1,243 new developed UC were sorted from 98,243 ESRD patients. Having been prescribed of esAA and acetaminophen increased risk significantly for UC. Significantly increased risk of lower tract UC if Mu Tong ever been prescribed, and at upper tract UC became significant at consumption more than 60 g. At chemoprevention agents, significant reduced hazard of UC in cases having been prescribed statin and aspirin in cases without exposure or less than esAA of 100 mg. More than 100 mg consumption the benefit will become marginal.
Conclusions: Consumption of aristolochic acid-related Chinese herbal products was associated with an increased risk of developing UC in ESRD patients. After decline in prescription of AA-CHP during study period, we found a similar trend in female UTUC incidence. The time trends associate with the consumption of aristolochic acid. Exception to AA-CHP consumption, acetaminophen is also a potential causal factor. Promising chemopreventive effect is found at aspirin and statin usage, but more than 100 mg AA consumption this effect is not promising. In conclusion, although AA-CHP consumption is decreasing, hazard of UC in ESRD patients was still high in end of 2008. Consumption of aristolochic acid herbal products implicitly impact public health in this generation. Although more understanding of causal and prevention factors are encouraging, developing practically regulations are indeed urgent.

並列關鍵字

Urothelial cancer ； end-stage renal disease ； aristolochic acid, ； acetaminophen ； non-steroidal anti-inflammatory drug ； aspirin ； statin ； SIR ； CIR

參考文獻

58. 戴正偉. 砷代謝能力、微量營養素與慢性腎臟病及腎臟功能之相關性研究. 台北市: 公共衛生學研究所, 臺北醫學大學; 2008.

113. Hsu Y, Tseng H, Wen K. Determination of aristolochic acid in Fangchi radix. Ann. Rept. NLFD Taiwan R.O.C. 1997(15):136-142 (In Chinese).

116. Chuang M, Hsu Y, Chang H, Lin J, Liao C. Studies on adulteration and misusage of marketed Akebiae caulisn. Ann. Rept. NLFD Taiwan R.O.C. 2002(20):104-119 (In Chinese).

118. Hsu Y, Lo C, Chang H, Lin J. Studies on adulteration and misusage of Asari radi in the market. Ann. Rept. NLFD Taiwan R.O.C. 2003(21):153-167 (In Chinese).

159. Tanaka T, Miyazawa K, Tsukamoto T, Kuno T, Suzuki K. Pathobiology and chemoprevention of bladder cancer. Journal of oncology. 2011;2011:528353.